Cytomel (Liothyronine) Cost in Pennsylvania 2026

What Does Generic Liothyronine Actually Cost in Pennsylvania?

Generic liothyronine is the most affordable route to T3 therapy in Pennsylvania, with an average retail cash price of roughly $35 per month in 2026. A 30-tablet supply of 25 mcg tablets at major Pennsylvania chains, including CVS, Rite Aid, Walmart, and Giant Food pharmacies, falls between $14 and $55 depending on the specific chain and whether a discount card is applied. The brand-name Cytomel (manufactured by Pfizer) carries a list price near $120 per month, though almost no patient pays that amount out of pocket once manufacturer savings cards or insurance are applied.

Liothyronine is a synthetic form of triiodothyronine (T3), the more metabolically active of the two principal thyroid hormones [1]. It is FDA-approved for hypothyroidism, pituitary TSH suppression in thyroid cancer, and as a diagnostic agent in thyroid suppression testing [2]. Off-label use alongside levothyroxine (T4) for combination thyroid therapy has grown steadily since Bunevicius et al. published their landmark NEJM trial in 1999, which found that replacing 50 mcg of levothyroxine with 12.5 mcg of liothyronine improved mood and neuropsychological function in 33 of 33 hypothyroid patients [3].

Price variation across Pennsylvania is real. Philadelphia-area pharmacies tend to run slightly higher than rural central Pennsylvania locations. Discount aggregators such as GoodRx, RxSaver, and NeedyMeds can compress the price to $14, $18 per month for a 25 mcg, 30-count supply at Costco or Walmart pharmacy locations in Pennsylvania [4]. The table below shows representative 2026 price ranges; actual prices shift with pharmacy contracts and coupon availability.

| Pharmacy | Cash Price (no coupon) | With Discount Card | |---|---|---| | CVS (PA avg.) | $45/mo | $22/mo | | Walmart (PA) | $20/mo | $14/mo | | Rite Aid (PA) | $50/mo | $25/mo | | Giant Food (PA) | $38/mo | $19/mo | | Independent (PA avg.) | $55/mo | $28/mo |

The FDA's Orange Book confirms that multiple generic liothyronine manufacturers hold AB-rated approval, meaning they are therapeutically equivalent to Cytomel and legally substitutable in Pennsylvania [2]. Pennsylvania allows generic substitution by default unless a prescriber writes "dispense as written."

Does Pennsylvania Medicaid Cover Liothyronine?

Pennsylvania Medicaid (Medical Assistance) covers liothyronine for hypothyroidism and related thyroid conditions, though coverage requires prior authorization in most managed care plans. Pennsylvania HealthChoices, the dominant Medicaid managed care program covering more than 2.7 million Pennsylvanians, places liothyronine on its preferred drug list with a PA requirement tied to documented clinical need, typically an inadequate response to levothyroxine monotherapy or a prescriber's documentation of combination therapy rationale [5].

Prior authorization is not automatic denial. PA forms for liothyronine under HealthChoices generally require a copy of recent thyroid labs (TSH, free T4, free T3), a diagnosis code (typically E03.9 for hypothyroidism, unspecified), and a note explaining why T4 monotherapy is insufficient. Most approvals are processed within 3 business days under Pennsylvania's standard PA turnaround rules.

The American Thyroid Association's 2012 guidelines, still referenced in most PA coverage determinations, state that "data do not support the routine use of combination T4 and T3 therapy" but acknowledge that "some patients may prefer combination therapy" [6]. That language gives prescribers documented grounds for individualized treatment decisions, which supports PA approval when framed correctly. Patients receiving liothyronine solely for thyroid cancer TSH suppression may qualify for coverage without a PA under oncology carve-outs in certain Pennsylvania Medicaid MCO contracts.

Medicare Part D covers generic liothyronine on most Pennsylvania plan formularies at Tier 1 or Tier 2 cost-sharing, with typical copays of $0, $10 per month for low-income subsidy (LIS) beneficiaries [7].

Is Compounded Liothyronine T3 Legal in Pennsylvania?

Compounded liothyronine T3 is legal in Pennsylvania when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber [8]. Pennsylvania's State Board of Pharmacy regulates 503A compounders and requires them to follow USP Chapter 795 standards for non-sterile compounding. Liothyronine powder is not a commercially available bulk drug substance prohibited by the FDA for 503A compounding, so pharmacies may legally use it to prepare custom-dose oral capsules or tablets.

Why would a patient choose compounded T3 over generic liothyronine? Several reasons exist. Some patients need non-standard doses (for example, 7.5 mcg or 15 mcg) that commercial tablets do not offer in a single unit. Others prefer sustained-release (SR) compounded formulations, which some clinicians prescribe to blunt the sharp serum T3 peak seen after immediate-release liothyronine. The evidence base for SR T3 is limited: a small study by Celi et al. (N=14) showed that SR T3 produced more stable serum T3 levels than immediate-release tablets, but no large randomized trial has confirmed a clinical benefit [9].

Compounded liothyronine costs approximately $40 per month in Pennsylvania, slightly above the generic cash price but below brand Cytomel. Patients should confirm that the chosen compounding pharmacy holds an active Pennsylvania State Board of Pharmacy registration and, ideally, PCAB (Pharmacy Compounding Accreditation Board) accreditation. The FDA's 503B outsourcing facility pathway is generally not relevant for individual patient-specific T3 prescriptions; that route applies to large-volume, non-patient-specific compounding [8].

Pennsylvania prescribers writing for compounded T3 should specify: drug name (liothyronine), dose in micrograms, release type (immediate or sustained), quantity, days' supply, and the clinical rationale. Vague prescriptions can be rejected by compounding pharmacies under USP 795 documentation requirements.

How Does Insurance Cover Cytomel and Generic Liothyronine in Pennsylvania?

Most commercial insurance plans sold in Pennsylvania, including Highmark, Independence Blue Cross (IBC), UPMC Health Plan, Aetna, and Cigna, cover generic liothyronine on Tier 1 or Tier 2 of their formularies. Brand-name Cytomel by Pfizer typically sits at Tier 3 or Tier 4, with monthly copays ranging from $40 to $150 depending on the plan design. Patients prescribed brand Cytomel by a physician who checks "dispense as written" may face higher cost-sharing unless they obtain a formulary exception [10].

Formulary exceptions in Pennsylvania are governed by Act 146 of 2014 (the Pennsylvania Insurance Fair Competition Act) and federal ACA rules requiring a timely exception process. A prescriber can submit a formulary exception request documenting medical necessity for brand Cytomel over generic alternatives; plans must respond within 72 hours for standard requests and 24 hours for expedited (urgent) requests.

Pfizer's savings card for Cytomel is available to commercially insured patients in Pennsylvania. Eligible patients may pay as little as $4 per 30-day fill at participating pharmacies. The savings card does not apply to patients covered by any federal or state government insurance program, including Medicare, Medicaid, CHIP, or TRICARE [11]. Patients should verify current terms at the Pfizer patient assistance portal, as copay cap amounts change annually.

For uninsured Pennsylvania residents earning up to 200% of the federal poverty level, the Pfizer RxPathways program provides Cytomel at no cost [11]. Generic liothyronine manufacturers (including Lannett, Genco, and Sigmapharm) do not currently offer patient assistance programs directly, but independent programs like NeedyMeds.org list pharmacy-specific vouchers and state pharmaceutical assistance options [4].

The Pennsylvania Pharmaceutical Assistance Contract for the Elderly (PACE) covers liothyronine for qualifying Pennsylvania residents aged 65 and older with annual incomes below $33,500 (single) or $41,500 (married) as of 2025 enrollment criteria [5]. Monthly copays under PACE are $8 per prescription.

What Are the Actual Drug Doses and Dosing Frequencies Used in Pennsylvania Practice?

Standard clinical dosing of liothyronine in Pennsylvania follows ATA and Endocrine Society recommendations. For hypothyroidism, typical starting doses range from 5 to 25 mcg per day, with maintenance doses usually between 25 and 75 mcg per day taken in divided doses [6]. Because liothyronine has a half-life of approximately 1 to 2 days, twice-daily dosing reduces peak-to-trough serum T3 fluctuations compared to once-daily administration [12].

When used as an add-on to levothyroxine for combination T4/T3 therapy, the Bunevicius protocol substituted 12.5 mcg of liothyronine for every 50 mcg of levothyroxine removed, maintaining total thyroid hormone equivalence [3]. A follow-up meta-analysis by Idrees et al. (2020, N=1,216 across 14 RCTs) found no statistically significant benefit for combination therapy on most quality-of-life measures but noted a meaningful subset of patients who reported subjective preference for T4/T3 combination versus T4 alone [13]. That preference data has shaped guidelines toward individualized, shared decision-making rather than a one-size policy.

For thyroid cancer TSH suppression, doses may reach 75 to 100 mcg daily under oncologist supervision, with TSH targets below 0.1 mIU/L for high-risk disease per ATA thyroid cancer management guidelines [6]. At those doses, cardiac monitoring is warranted, particularly in patients over age 60 or with known atrial fibrillation risk factors.

Pediatric dosing in Pennsylvania follows weight-based protocols; the FDA label specifies starting doses of 5 mcg daily in children and elderly patients, titrated in 5 mcg increments every 1 to 2 weeks [2].

Can I Get a Liothyronine Prescription via Telehealth in Pennsylvania?

Telehealth prescribing of liothyronine is fully legal in Pennsylvania in 2026. Pennsylvania's telehealth law (Act 92 of 2020) authorizes licensed Pennsylvania prescribers to evaluate, diagnose, and prescribe Schedule and non-Schedule medications via synchronous audio-video or, in some circumstances, audio-only modalities [5]. Liothyronine is not a controlled substance, so it does not trigger the additional Ryan Haight Act requirements that apply to medications like testosterone or stimulants.

A telehealth visit for liothyronine in Pennsylvania must include a clinical evaluation sufficient to establish a valid prescriber-patient relationship. That means a licensed Pennsylvania clinician must review the patient's thyroid labs, medical history, and current medications before writing the prescription. No Pennsylvania law requires an in-person visit before a telehealth T3 prescription, though individual health system policies may differ from the statutory minimum.

HealthRX clinicians licensed in Pennsylvania conduct thyroid consultations via telemedicine and can prescribe liothyronine when clinically appropriate. Patients typically need to provide results of TSH, free T4, and free T3 drawn within the past 6 months. A baseline resting heart rate and blood pressure are also reviewed given liothyronine's cardiac effects [2].

The Endocrine Society's 2019 clinical practice guidelines on hypothyroidism state that "the decision to use combination T4 plus T3 treatment should be made jointly by the patient and clinician," and explicitly note that patient preference is a legitimate clinical factor [14]. Telehealth settings are fully capable of supporting that shared decision-making discussion.

What Is the Cheapest Way to Get Liothyronine in Pennsylvania?

The lowest-cost option for most Pennsylvania patients without insurance is generic liothyronine purchased with a free discount card at a low-cost pharmacy. Walmart Pharmacy in Pennsylvania consistently offers the lowest base price, and combining that with a GoodRx or RxSaver coupon can bring a 30-day supply of 25 mcg tablets to $14 [4]. That is 88% below the Pfizer Cytomel list price.

A practical cost hierarchy for Pennsylvania patients in 2026 runs as follows. The first option is Medicare Part D with LIS (low-income subsidy), which can reduce cost to $0 to $4 per month [7]. The second option is Pennsylvania Medicaid (HealthChoices) after prior authorization approval, bringing cost to $1 to $3 per month for most beneficiaries. The third option is commercial insurance Tier 1 generic copay, typically $5 to $15 per month at major Pennsylvania plans. The fourth option is GoodRx or RxSaver coupon at Walmart or Costco, reaching $14 to $18 per month with no insurance needed. The fifth option is PACE program for qualifying Pennsylvania seniors at $8 per prescription. The sixth option is Pfizer RxPathways patient assistance for uninsured patients meeting income criteria, providing Cytomel at no cost [11]. Compounded liothyronine from a Pennsylvania 503A pharmacy runs approximately $40 per month and makes sense when non-standard dosing is required, not as a cost-saving measure.

Splitting tablets is not recommended for liothyronine because the tablets are small (5, 25, and 50 mcg sizes) and precise dosing is important for thyroid management. Dose adjustments should always be made in consultation with a prescribing clinician [2].

How Do Thyroid Labs Affect Liothyronine Dosing and Cost Over Time?

Monitoring requirements directly affect total out-of-pocket cost for Pennsylvania patients on liothyronine. Clinical guidelines recommend TSH and free T3 measurement 4 to 6 weeks after any dose change and every 6 to 12 months once stable [6]. In Pennsylvania, a standard outpatient thyroid panel (TSH plus free T3 and free T4) costs $30 to $120 at Quest or LabCorp without insurance; most Pennsylvania commercial plans cover these labs at 100% after meeting the deductible when ordered by a treating physician.

The dose stability data matter for budgeting. Once a patient reaches their maintenance dose, prescription refills typically run at a fixed monthly cost with annual lab checks, making liothyronine a predictable line item in a chronic disease medication budget. Patients started on 25 mcg daily rarely require dose adjustments more frequently than twice per year after the first 6 months of therapy [12].

Overdose risk is real. Symptoms of excess liothyronine, including palpitations, heat intolerance, weight loss, and diarrhea, typically appear when free T3 rises above the upper reference range [2]. Pennsylvania prescribers are required to document informed consent discussions covering these risks, particularly for patients with cardiovascular disease, before initiating liothyronine [14].

Monitoring Cardiovascular Risk in Pennsylvania Patients on Liothyronine

Liothyronine's cardiac effects are the primary safety concern that differentiates it from levothyroxine in clinical practice. T3 directly increases heart rate, myocardial contractility, and systolic blood pressure by binding thyroid hormone receptors in cardiac tissue [12]. A 2017 analysis published in the Journal of Clinical Endocrinology and Metabolism found that supraphysiologic free T3 levels were associated with a 2.4-fold increased risk of atrial fibrillation in a cohort of 2,143 thyroid patients followed over 5 years [15].

Pennsylvania prescribers following standard-of-care guidelines should assess baseline ECG, heart rate, and blood pressure before starting liothyronine in any patient over age 50 or with known cardiovascular disease [6]. Dose titration should proceed in 5 mcg increments, with at least 2 weeks between increases, to avoid abrupt T3 surges [2]. Patients on anticoagulants such as warfarin require particularly close monitoring; liothyronine potentiates warfarin's anticoagulant effect and may require downward warfarin dose adjustments after T3 initiation [2].

These monitoring requirements do not substantially increase total therapy cost for most Pennsylvania patients, as cardiovascular assessments are typically bundled into regular primary care visits covered by insurance. The incremental annual cost of appropriate liothyronine monitoring for a stable Pennsylvania patient on a standard commercial plan runs approximately $50 to $200 in copays beyond the drug cost itself [7].